Pasithea <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Receives Nasdaq Notice for Non-Compliance with $1 Minimum Bid Price Rule
Pasithea Therapeutics Corporation has announced that it received a notice from the Nasdaq Stock Market on June 23, 2025, indicating non-compliance with the $1.00 minimum bid price requirement necessary for continued listing on the Nasdaq Capital Market. This notice does not lead to immediate delisting of the company's common stock. Pasithea has 180 calendar days, until December 22, 2025, to regain compliance by ensuring its stock closes at or above $1.00 per share for at least ten consecutive business days. The company is exploring options, including a potential reverse stock split, to address the issue. If compliance is not regained within this period, an additional 180-day period may be available, provided other listing criteria are met. Failure to comply could result in delisting, subject to appeal. This development does not affect the company's operations or SEC reporting requirements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-059004), on June 27, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。